Literature DB >> 24812133

International adaptations of NCCN Clinical Practice Guidelines in Oncology.

Robert W Carlson1, Jonathan K Larsen, Joan McClure, C Lyn Fitzgerald, Alan P Venook, Al B Benson, Benjamin O Anderson.   

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are evidence- and consensus-based clinical practice guidelines addressing malignancies that affect more than 97% of all patients with cancer in the United States. The NCCN Guidelines are used extensively in the United States and globally. Use of the guidelines outside the United States has driven the need to adapt the guidelines based on local, regional, or national resources. The NCCN Guidelines Panels created, vetted, and continually update the NCCN Guidelines based on published scientific data on cancer detection, diagnosis, and treatment efficacy. The guidelines are developed within the context of commonly available resources, methods of payment, societal and cultural expectations, and governmental regulations as they exist in the United States. Although many of the cancer management recommendations contained in the NCCN Guidelines apply broadly from a global perspective, not all do. Disparities in availability and access to health care exist among countries, within countries, and among different social groups in the same country, especially regarding resources for cancer prevention, early detection, and treatment. In addition, different drug approval and payment processes result in regional variation in availability of and access to cancer treatment, especially highly expensive agents and radiation therapy. Differences in cancer risk, predictive biomarker expression, and pharmacogenetics exist across ethnic and racial groups, and therefore across geographic locations. Cultural and societal expectations and requirements may also require modification of NCCN Guidelines for use outside the United States. This article describes the adaptation process, using the recent Latin American adaptation of the 2013 NCCN Guidelines for Colorectal Cancer as an example.

Entities:  

Mesh:

Year:  2014        PMID: 24812133     DOI: 10.6004/jnccn.2014.0068

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  15 in total

Review 1.  Forging a New Frontier: Providing Palliative Care to People With Cancer in Rural and Remote Areas.

Authors:  Marie Bakitas; Kristen Allen Watts; Emily Malone; J Nicholas Dionne-Odom; Susan McCammon; Richard Taylor; Rodney Tucker; Ronit Elk
Journal:  J Clin Oncol       Date:  2020-02-05       Impact factor: 44.544

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 3.  Precision Medicine in Low- and Middle-Income Countries.

Authors:  Jerald P Radich; Edward Briercheck; Daniel T Chiu; Manoj P Menon; Olga Sala Torra; Cecilia C S Yeung; Edus H Warren
Journal:  Annu Rev Pathol       Date:  2022-01-24       Impact factor: 32.350

4.  Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study.

Authors:  Hye Jung Park; Heae Surng Park; Yoon Jin Cha; Sungsoo Lee; Hei-Cheul Jeung; Jae Yong Cho; Hyung Jung Kim; Min Kwang Byun
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

5.  Expression of tumor necrosis factor α-induced protein 8 is upregulated in human gastric cancer and regulates cell proliferation, invasion and migration.

Authors:  Yansen Li; Changqing Jing; Yuezhi Chen; Jinshen Wang; Mingliang Zhou; Xin Liu; Dong Sun; Linjun Mu; Leping Li; Xiaobo Guo
Journal:  Mol Med Rep       Date:  2015-04-27       Impact factor: 2.952

6.  Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model.

Authors:  Hyo Joon Jang; Sukki Cho; Kwhanmien Kim; Sanghoon Jheon; Hee Chul Yang; Dong Kwan Kim
Journal:  Cancer Res Treat       Date:  2017-01-18       Impact factor: 4.679

7.  Natural product pectolinarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway.

Authors:  Tianchun Wu; Xiaogang Dong; Dongdong Yu; Zhenhua Shen; Jinbei Yu; Sheng Yan
Journal:  Onco Targets Ther       Date:  2018-12-03       Impact factor: 4.147

8.  External Radiation versus Internal Radiation for Patients with Advanced Unresectable HCC -A SEER Based Study.

Authors:  Xuan Wang; Mo Chen; Ran Wei; Zheng Wang
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

9.  Characterization of long non-coding RNA expression profiles in lymph node metastasis of early-stage cervical cancer.

Authors:  Chunliang Shang; Wenhui Zhu; Tianyu Liu; Wei Wang; Guangxin Huang; Jiaming Huang; Peizhen Zhao; Yunhe Zhao; Shuzhong Yao
Journal:  Oncol Rep       Date:  2016-03-29       Impact factor: 3.906

10.  Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma.

Authors:  Dong Xie; Ting-Ting Wang; Shu-Jung Huang; Jia-Jun Deng; Yi-Jiu Ren; Yang Yang; Jun-Qi Wu; Lei Zhang; Ke Fei; Xi-Wen Sun; Yun-Lang She; Chang Chen
Journal:  Transl Lung Cancer Res       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.